BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Risitano AM. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 2012;217:1080-7. [PMID: 22964233 DOI: 10.1016/j.imbio.2012.07.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Speth C, Rambach G, Würzner R, Lass-flörl C, Kozarcanin H, Hamad OA, Nilsson B, Ekdahl KN. Complement and platelets: Mutual interference in the immune network. Molecular Immunology 2015;67:108-18. [DOI: 10.1016/j.molimm.2015.03.244] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
2 de la Morena-Barrio ME, Hernández-Caselles T, Corral J, García-López R, Martínez-Martínez I, Pérez-Dueñas B, Altisent C, Sevivas T, Kristensen SR, Guillén-Navarro E, Miñano A, Vicente V, Jaeken J, Lozano ML. GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. Orphanet J Rare Dis 2013;8:170. [PMID: 24139637 DOI: 10.1186/1750-1172-8-170] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
3 Ghosh P, Sahoo R, Vaidya A, Chorev M, Halperin JA. Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev. 2015;36:272-288. [PMID: 25859860 DOI: 10.1210/er.2014-1099] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 10.6] [Reference Citation Analysis]
4 Thurman JM, Frazer-Abel A, Holers VM. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol 2017;69:2102-13. [PMID: 28732131 DOI: 10.1002/art.40219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
5 Frieri C, Peffault de Latour R, Sicre De Fontbrune F. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Emerg Drugs 2022. [PMID: 35078384 DOI: 10.1080/14728214.2022.2031973] [Reference Citation Analysis]
6 Chimenti MS, Ballanti E, Triggianese P, Perricone R. Vasculitides and the Complement System: a Comprehensive Review. Clin Rev Allergy Immunol 2015;49:333-46. [PMID: 25312590 DOI: 10.1007/s12016-014-8453-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
7 Gurnari C, Nautiyal I, Pagliuca S. Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Ther Clin Risk Manag 2021;17:1343-51. [PMID: 34934322 DOI: 10.2147/TCRM.S273360] [Reference Citation Analysis]
8 Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol 2016;31:3-17. [PMID: 26332138 DOI: 10.1111/omi.12129] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
9 Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12:383-401. [PMID: 27211870 DOI: 10.1038/nrneph.2016.70] [Cited by in Crossref: 248] [Cited by in F6Publishing: 246] [Article Influence: 41.3] [Reference Citation Analysis]
10 Risitano AM. Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Semin Hematol 2018;55:113-7. [PMID: 30032746 DOI: 10.1053/j.seminhematol.2018.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Su H, Liu X, Du J, Deng X, Fan Y. The role of hemoglobin in nitric oxide transport in vascular system. Medicine in Novel Technology and Devices 2020;5:100034. [DOI: 10.1016/j.medntd.2020.100034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Pagliuca S, Risitano AM, De Fontbrune FS, Robin M, Iori AP, Marotta S, Michonneau D, Villate A, Desmier D, Socié G, De Latour RP. Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. Bone Marrow Transplant 2018;53:105-7. [DOI: 10.1038/bmt.2017.220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
13 Dulau-florea A, Maric I, Calvo KR, Braylan RC. Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates☆. Seminars in Hematology 2019;56:65-8. [DOI: 10.1053/j.seminhematol.2018.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Gurnari C, Pagliuca S, Patel BJ, Awada H, Kongkiatkamon S, Terkawi L, Zawit M, Corey S, Lichtin AE, Carraway HE, Wahida A, Visconte V, Maciejewski JP. Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. Leukemia 2021;35:2431-4. [PMID: 33483614 DOI: 10.1038/s41375-020-01113-0] [Reference Citation Analysis]
15 Senent Y, Ajona D, González-Martín A, Pio R, Tavira B. The Complement System in Ovarian Cancer: An Underexplored Old Path. Cancers (Basel) 2021;13:3806. [PMID: 34359708 DOI: 10.3390/cancers13153806] [Reference Citation Analysis]
16 Iyer A, Xu W, Reid RC, Fairlie DP. Chemical Approaches to Modulating Complement-Mediated Diseases. J Med Chem 2018;61:3253-76. [DOI: 10.1021/acs.jmedchem.7b00882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Dulau-Florea AE, Young NS, Maric I, Calvo KR, Dunbar CE, Townsley DM, Winkler T, Monreal M, Jiang C, Jordan EK, Braylan RC. Bone Marrow as a Source of Cells for Paroxysmal Nocturnal Hemoglobinuria Detection. Am J Clin Pathol 2018;150:273-82. [PMID: 29982419 DOI: 10.1093/ajcp/aqy053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123:2094-2101. [PMID: 24497537 DOI: 10.1182/blood-2013-11-536573] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 15.4] [Reference Citation Analysis]
19 Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015;14:857-77. [PMID: 26493766 DOI: 10.1038/nrd4657] [Cited by in Crossref: 227] [Cited by in F6Publishing: 210] [Article Influence: 32.4] [Reference Citation Analysis]
20 Maldonado-Báez L, Williamson C, Donaldson JG. Clathrin-independent endocytosis: a cargo-centric view. Exp Cell Res 2013;319:2759-69. [PMID: 23954817 DOI: 10.1016/j.yexcr.2013.08.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 7.4] [Reference Citation Analysis]
21 Garaulet G, Lazcano JJ, Alarcón H, de Frutos S, Martínez-Torrecuadrada JL, Rodríguez A. Display of the Albumin-Binding Domain in the Envelope Improves Lentiviral Vector Bioavailability. Hum Gene Ther Methods 2017;28:340-51. [PMID: 29160106 DOI: 10.1089/hgtb.2017.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Warwick CA, Keyes AL, Woodruff TM, Usachev YM. The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. J Biol Chem 2021;297:101085. [PMID: 34411562 DOI: 10.1016/j.jbc.2021.101085] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol 2018;55:167-75. [PMID: 30032754 DOI: 10.1053/j.seminhematol.2018.02.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
24 Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology 2016;221:1046-57. [PMID: 27353192 DOI: 10.1016/j.imbio.2016.06.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
25 Mastellos DC, Ricklin D, Yancopoulou D, Risitano A, Lambris JD. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol 2014;7:583-98. [PMID: 25213458 DOI: 10.1586/17474086.2014.953926] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
26 Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013;190:3839-3847. [PMID: 23564578 DOI: 10.4049/jimmunol.1203200] [Cited by in Crossref: 162] [Cited by in F6Publishing: 145] [Article Influence: 18.0] [Reference Citation Analysis]
27 Ivanov PA, Faktor MI, Karpova NS, Cheremnykh EG, Brusov OS. Complement-Mediated Death of Ciliate Tetrahymena pyriformis Caused by Human Blood Serum. Bull Exp Biol Med 2016;160:775-8. [PMID: 27169636 DOI: 10.1007/s10517-016-3307-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Tomaiuolo G. Biomechanical properties of red blood cells in health and disease towards microfluidics. Biomicrofluidics. 2014;8:051501. [PMID: 25332724 DOI: 10.1063/1.4895755] [Cited by in Crossref: 178] [Cited by in F6Publishing: 134] [Article Influence: 22.3] [Reference Citation Analysis]
29 Hebecker M, Alba-Domínguez M, Roumenina LT, Reuter S, Hyvärinen S, Dragon-Durey MA, Jokiranta TS, Sánchez-Corral P, Józsi M. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 2013;191:912-21. [PMID: 23772024 DOI: 10.4049/jimmunol.1300269] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
30 Cao H, Zhang G, Ciociola K, Amaravadi L, Qiu Y, Wu J. An LC–MS/MS approach to assess total and free protein target in the serum of cynomolgus monkey. Bioanalysis 2019;11:393-406. [DOI: 10.4155/bio-2018-0294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 McDonald CR, Tran V, Kain KC. Complement Activation in Placental Malaria. Front Microbiol 2015;6:1460. [PMID: 26733992 DOI: 10.3389/fmicb.2015.01460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
32 Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20:171-9. [PMID: 33249943 DOI: 10.1080/14740338.2021.1857723] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Vogel C, Fritzinger D, Gorsuch B, Stahl G. Complement depletion with humanised cobra venom factor: Efficacy in preclinical models of vascular diseases. Thromb Haemost 2017;113:548-52. [DOI: 10.1160/th14-04-0300] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
34 Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2017;110:910-9. [DOI: 10.1160/th13-02-0102] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
35 Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv 2019;3:3575-8. [PMID: 31738828 DOI: 10.1182/bloodadvances.2019000897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Zhang L, Chen JY, Kerr C, Cobb BA, Maciejewski JP, Lin F. Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria. Leukemia 2021;35:1176-87. [PMID: 32814838 DOI: 10.1038/s41375-020-1008-5] [Reference Citation Analysis]
37 Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013;190:3831-8. [PMID: 23564577 DOI: 10.4049/jimmunol.1203487] [Cited by in Crossref: 288] [Cited by in F6Publishing: 276] [Article Influence: 32.0] [Reference Citation Analysis]
38 Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol 2019;10:1157. [PMID: 31258525 DOI: 10.3389/fimmu.2019.01157] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
39 Luo S, Hu D, Wang M, Zipfel PF, Hu Y. Complement in Hemolysis- and Thrombosis- Related Diseases. Front Immunol 2020;11:1212. [PMID: 32754149 DOI: 10.3389/fimmu.2020.01212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
40 Alipanahzadeh H, Ghulamreza R, Shokouhian M, Bagheri M, Maleknia M. Deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders. J Thromb Thrombolysis 2020;50:318-29. [PMID: 31808122 DOI: 10.1007/s11239-019-02005-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Freitas Leal JK, Preijers F, Brock R, Adjobo-Hermans M, Bosman G. Red Blood Cell Homeostasis and Altered Vesicle Formation in Patients With Paroxysmal Nocturnal Hemoglobinuria. Front Physiol 2019;10:578. [PMID: 31156458 DOI: 10.3389/fphys.2019.00578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
42 Risitano AM, Peffault de Latour R. How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol 2021. [PMID: 34355382 DOI: 10.1111/bjh.17753] [Reference Citation Analysis]
43 Martí-Carvajal AJ, Anand V, Cardona AF, Solà I. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria. Cochrane Database Syst Rev 2014;:CD010340. [PMID: 25356860 DOI: 10.1002/14651858.CD010340.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
44 Bareke H, Akbuga J. Complement system's role in cancer and its therapeutic potential in ovarian cancer. Scand J Immunol 2018;88:e12672. [PMID: 29734524 DOI: 10.1111/sji.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
45 Subías M, Tortajada A, Gastoldi S, Galbusera M, López-Perrote A, Lopez Lde J, González-Fernández FA, Villegas-Martínez A, Dominguez M, Llorca O, Noris M, Morgan BP, Rodríguez de Córdoba S. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models. J Immunol 2014;193:5567-75. [PMID: 25355917 DOI: 10.4049/jimmunol.1402013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
46 Subías Hidalgo M, Yébenes H, Rodríguez-Gallego C, Martín-Ambrosio A, Domínguez M, Tortajada A, Rodríguez de Córdoba S, Llorca O. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications. Eur J Immunol 2017;47:504-15. [PMID: 28083930 DOI: 10.1002/eji.201646758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
47 Caruso A, Vollmer J, Machacek M, Kortvely E. Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease. PLoS Comput Biol 2020;16:e1008139. [PMID: 33006965 DOI: 10.1371/journal.pcbi.1008139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Mastellos DC, Yancopoulou D, Kokkinos P, Huber-lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest 2015;45:423-40. [DOI: 10.1111/eci.12419] [Cited by in Crossref: 122] [Cited by in F6Publishing: 115] [Article Influence: 17.4] [Reference Citation Analysis]